Curated News
By: NewsRamp Editorial Staff
November 10, 2026
Novus Posts 7.78% Revenue Growth, Adds Upscale to Cannabis Network
TLDR
- Novus Acquisition & Development Corp. (NDEV) posted 7.78% revenue growth with zero convertible debt and a 9.74% debt-to-equity ratio, giving it a low-risk edge in cannabis health benefits.
- NDEV generates revenue solely from member plan fees and insurance premiums, using a non-plant-touching model that avoids Section 280E taxes and provides 25% to 30% net out-of-pocket savings.
- Novus Cannabis MedPlan expands access to cannabis-inclusive health coverage, helping 65 million Americans afford alternative medicine through discounts and pre-tax HSA/FSA savings.
- NDEV onboarded Upscale, an NSF Certified for Sport, THC-free provider, and reports 0% insider share liquidation over 36 months with a 100% vendor share leak-out provision.
Impact - Why it Matters
This news matters because Novus is carving out a compliant, non-plant-touching model in the cannabis-adjacent health benefits space, which could serve as a blueprint for insurers navigating federal scheduling uncertainties. The company’s ability to offer significant member discounts while avoiding Section 280E tax burdens demonstrates a scalable approach to integrating alternative medicine into structured benefits programs. For investors, the disciplined capital structure—zero convertible debt and no insider liquidation—signals stability in a volatile sector. For consumers, the expansion of the provider network with Upscale means access to institutional-grade, THC-free products that meet rigorous NSF Certified for Sport standards, potentially broadening acceptance in corporate and athletic environments. As medical marijuana gains mainstream traction, Novus’s dual-platform strategy positions it to capture a share of the 65 million American market while mitigating regulatory and financial risks.
Summary
Novus Acquisition & Development Corp. (OTC: NDEV), operating through its wholly owned subsidiary WCIG Insurance Services, Inc. as Novus Cannabis MedPlan, has announced interim financial results for the nine-month period ending September 30, 2026. The company reported a 7.78% year-over-year increase in gross revenue, a 2.34% year-to-date expansion in total assets, and a 2.26% rise in stockholders’ equity. Novus also highlighted a highly unleveraged capital structure, with a debt-to-equity ratio of 9.74% and 0% convertible debt among its total liabilities. Corporate governance measures remain strict, including 0% insider share liquidation over the trailing 36-month period and a 100% active Vendor Share Leak-Out Provision to mitigate dilution.
Operating strictly as a health plan carrier and benefits administrator, Novus derives all revenues from member plan fees and insurance premiums rather than the direct sale of controlled substances. The company is targeting an estimated 65 million Americans who view medical marijuana as a primary alternative healthcare focus. To support this, Novus has onboarded a new commercial provider, Upscale (www.shopupscalecbd.com), which delivers institutional-grade, broad-spectrum, THC-free formulations manufactured in an NSF GMP-compliant facility in Phoenix, Arizona. Upscale’s portfolio carries the NSF Certified for Sport designation, supporting compliance and strategic alignment within high-performance and regulated athletic environments.
For investors, NDEV emphasizes its proprietary dual-platform infrastructure and non-plant-touching business model, which maintains 100% operational segregation between its prescription drug plan and cannabis-adjacent distribution platform. This structure avoids federal cannabis scheduling delays and the heavy tax burdens of Internal Revenue Code Section 280E. The company reports that members achieve a net 25% to 30% reduction in gross out-of-pocket expenditure through a 35% to 40% direct product discount at the register combined with pre-tax purchasing power via Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA), which corresponds to an estimated 15% to 17% reduction in effective tax liability. For comprehensive financial statements and Q3 2026 highlights, visit the Investor Relations portal.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Novus Posts 7.78% Revenue Growth, Adds Upscale to Cannabis Network
